GLP-1 drugs — semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide (Mounjaro) — have transformed weight management. There is also growing interest in whether they can help with arthritis. For knee and hip osteoarthritis, this idea is interesting because a heavier body weight puts more load on these joints. So what does the evidence show, how are these drugs used, and what are the side effects? Does GLP 1 help with arthritis pain? 

What are GLP-1 drugs?

GLP-1 receptor agonists mimic a natural gut hormone that affects appetite and blood sugar. They were originally developed for diabetes and then for weight management, where they produce significant weight loss. The best-known are semaglutide (Ozempic and Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro). Mounjaro also acts on a second hormone receptor (GIP) and tends to produce the greatest weight loss.

Currently, doctors use these drugs for weight management in people with a body mass index (BMI) of 30 or above, or 27 or above when there’s another condition such as diabetes or high blood pressure. Notably, osteoarthritis is not yet on that list of qualifying conditions.

How is arthritis linked to weight?

Osteoarthritis of the knee and hip is strongly linked to body weight, and in two ways:

  • Load on the joint — every extra kilo of body weight increases the forces through the joint, accelerating cartilage wear.

 

  • Metabolic inflammation — Excess fat is not benign. It releases inflammation throughout the body, including joints and tendons. This inflammation actively damages cartilage and inflames the joint lining. 

Can GLP-1 drugs help arthritis? What the evidence shows

The strongest evidence comes from the STEP 9 trial, which studied people with obesity and moderate-to-severe knee osteoarthritis. Over a year, those given the drug lost around 13.7% of their body weight (versus about 3.2% on placebo). Importantly, their knee osteoarthritis pain improved significantly more than with placebo. The magnitude of improvement was better than that seen with anti-inflammatory drugs such as ibuprofen or duloxetine.

Supporting this, a large study of people with knee osteoarthritis and type 2 diabetes found that GLP-1 users lost more weight and had fewer knee surgeries. Moreover, people with repeat MRI scans showed a slower rate of cartilage loss than non-users. 

The amount of weight loss matters. Studies suggest that meaningful improvement in arthritis requires weight loss of around 7–10% or more. This matters because GLP-1 drugs are among the few treatments that achieve this level of weight loss. 

What the evidence does and doesn’t show 

It’s worth being straight about the evidence, because it’s promising but still early. A 2025 systematic review pulled together all the studies (both laboratory and human) of GLP-1 drugs in osteoarthritis, and the picture is nuanced:

  • The laboratory evidence is consistent. Across animal studies, GLP-1 drugs reliably protect cartilage and calm joint inflammation.

 

  • The human evidence is more mixed. Not every trial has been positive. Trials of liraglutide (an older, less potent GLP-1 drug) did not show a clear reduction in knee pain, even though people lost weight. It was the semaglutide STEP 9 trial, with much larger weight loss, that showed a clear pain benefit. In other words, the benefit so far seems closely tied to the amount of weight lost. So, we think that stronger drugs that produce more weight loss are showing positive results. 

 

  • Cartilage protection in humans is still unproven. Only one study has suggested slower cartilage loss on MRI.

The honest summary: high-quality trials are still needed to confirm how much of the benefit is the drug versus the weight loss, and whether these drugs truly protect the joint structure over time. 

How are GLP-1 drugs used?

GLP-1 drugs are given as a once-weekly injection under the skin with a pre-filled pen. The dose starts low and increases in steps over weeks or months to reduce side effects. A doctor prescribes and monitors them, checking progress, adjusting the dose, and watching for side effects. They work best alongside — not instead of — dietary change and exercise. The benefit continues only while the drug is taken; weight tends to return if it’s stopped. 

Side effects and cautions

GLP-1 drugs are generally well tolerated, but they do have side effects and aren’t suitable for everyone:

  • Gastrointestinal effects are the commonest — nausea, and sometimes vomiting, diarrhoea, constipation, or reflux. These are usually worst when starting or increasing the dose, and ease with time, which is why the dose is built up gradually.

 

  • Reduced appetite and early fullness — the intended effect, but it needs managing so that nutrition (especially protein) stays adequate — see the exercise section below.

 

  • Less common but important: gallbladder problems, pancreatitis (uncommon), and injection-site reactions.

 

  • Not suitable for everyone — they’re avoided in certain situations (including a personal or family history of specific thyroid cancers, and in pregnancy), which is one of several reasons they need proper medical assessment before starting.

This is exactly why these are prescription medications.

GLP-1 drugs and exercise: the key point for active people

Rapid weight loss — from any cause, including GLP-1 drugs — doesn’t only remove fat; it can also cause loss of muscle and, potentially, bone. For someone with arthritis, losing muscle is not good: strong muscles around a joint protect it and reduce pain. Losing weight but also losing muscle undermines the benefit you’re seeking.

So if GLP-1 drugs are used for arthritis, exercise is essential: 

  • Resistance (strengthening) training is needed to preserve muscle while losing fat and to strengthen the muscles that support the arthritic joint.

 

  • Adequate protein intake matters more than usual, because appetite is suppressed — it’s easy to under-eat protein and lose muscle. This is worth planning deliberately.

 

  • Low-impact aerobic exercise (cycling, swimming, walking) supports weight loss and joint health without overloading a painful joint.

 

  • A structured, progressive program balances progress and protection as you lose weight.

The best results in arthritis come from combining weight loss with exercise, so that you lose fat, keep muscle, and build the strength that protects the joint. GLP-1 drugs may make the weight loss achievable; exercise makes it count.

Where does this fit in arthritis treatment?

GLP-1 drugs are not a first-line treatment for arthritis. Moreover, they’re not a replacement for the basics — exercise, strengthening, weight management, and, where appropriate, injections or other measures. But for an overweight or obese person with knee or hip osteoarthritis who hasn’t been able to lose enough weight, they’re a potentially valuable addition to the plan. But use for osteoarthritis specifically is currently off-label — another reason this is a conversation to have with a doctor. For the wider picture, see our guide to the best treatment for arthritis and whether osteoarthritis can be reversed.

Frequently asked questions about GLP-1 and arthritis

Can GLP-1 drugs like Ozempic help arthritis pain?

The evidence is most developed for knee osteoarthritis in people with obesity, where semaglutide produced significant weight loss and a meaningful reduction in joint pain in a large trial (STEP 9). The benefit comes from both reduced joint load and direct anti-inflammatory effects. It’s most relevant when arthritis is linked to excess weight, and it works best combined with exercise.

How much weight do you need to lose for arthritis to improve?

Research suggests you generally need to lose about 7–10% of body weight (or more) to improve knee osteoarthritis. GLP-1 drugs are notable because they can achieve weight loss in that range with diet and exercise. The more weight lost, the greater the joint benefit tends to be.

Do GLP-1 drugs actually protect the joint, or reduce weight?

So far, the most reliable benefit comes through weight loss. But studies also show GLP-1 drugs can directly reduce joint inflammation and cartilage breakdown. But that direct, weight-independent protection hasn’t been proven in proper trials yet. So the fair answer today is: the weight-loss benefit is real; a direct joint-protecting effect is plausible but not yet confirmed in people. 

Will I lose muscle on a GLP-1 drug, and does that matter for arthritis?

Rapid weight loss from any cause can include muscle loss, and this matters a lot for arthritis, because strong muscles protect and support the joint. That’s why resistance exercise and adequate protein are so important while taking these drugs. Losing weight but also losing that muscle can make arthritis worse. 

Are GLP-1 drugs approved for arthritis?

Not yet. They’re approved for weight loss (at a BMI of 30+, or 27+ with a weight-related condition). Osteoarthritis isn’t yet on the list of qualifying conditions. This means using them for osteoarthritis specifically may be off-label. It’s a decision to make with a doctor, who can weigh up your overall health, weight, and other conditions.

Final word from Sport Doctor London about GLP-1 and arthritis

GLP-1 drugs are an exciting development for knee and hip osteoarthritis linked to excess weight. Evidence shows reduced pain and improved function alongside substantial weight loss. Hints suggest they may also act directly on the joint. They’re not a first-line treatment or a substitute for exercise and strengthening. Used in the right person, alongside a strengthening program that preserves muscle, they may become a valuable part of arthritis care. 

If you have knee or hip arthritis and want to understand your medical options, Dr Masci can assess you in London and discuss an evidence-based plan. Contact the team here or call +44 (0) 203 488 0350. 

Related conditions: